Literature DB >> 30157115

ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.

Delu Song1, Gui-Shuang Ying1, Joshua L Dunaief1, Rupak Bhuyan1, Yafeng Li1, Maureen G Maguire1, Juan E Grunwald1, Ebenezer Daniel1, Stephanie Hagstrom2, Daniel F Martin2.   

Abstract

PURPOSE: Because patients often take iron supplements without medical indication, and iron can accumulate in vascular endothelial cells, the authors evaluated the association of oral iron supplementation with retinal/subretinal hemorrhage in patients with neovascular age-related macular degeneration.
METHODS: A post hoc secondary data analysis of comparison of age-related macular degeneration treatments trials was performed. Participants were interviewed for use of oral iron supplements. Trained readers evaluated retinal/subretinal hemorrhage in baseline fundus photographs. Adjusted odds ratios from multivariate logistic regression models assessed the association between iron use and baseline hemorrhage adjusted by age, sex, smoking, hypertension, anemia, and use of antiplatelet/anticoagulant drugs.
RESULTS: Among 1,165 participants, baseline retinal/subretinal hemorrhage was present in the study eye in 71% of 181 iron users and in 61% of 984 participants without iron use (adjusted odds ratio = 1.47, P = 0.04), and the association was dose dependent (adjusted linear trend P = 0.048). Iron use was associated with hemorrhage in participants with hypertension (adjusted odds ratio = 1.87, P = 0.006) but not without hypertension. The association of iron use with hemorrhage remained significant among hypertensive participants without anemia (adjusted odds ratio = 1.85, P = 0.02).
CONCLUSION: Among participants of comparison of age-related macular degeneration treatments trials, the use of oral iron supplements was associated with retinal/subretinal hemorrhage in a dose-response manner. Unindicated iron supplementation may be detrimental in patients with wet age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30157115      PMCID: PMC6395574          DOI: 10.1097/IAE.0000000000002295

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  27 in total

1.  Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane.

Authors:  Paul Hahn; Ann H Milam; Joshua L Dunaief
Journal:  Arch Ophthalmol       Date:  2003-08

2.  Ocular effects of systemic siderosis.

Authors:  P A CIBIS; E B BROWN; S M HONG
Journal:  Am J Ophthalmol       Date:  1957-10       Impact factor: 5.258

3.  Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Kathy Radimer; Bernadette Bindewald; Jeffery Hughes; Bethene Ervin; Christine Swanson; Mary Frances Picciano
Journal:  Am J Epidemiol       Date:  2004-08-15       Impact factor: 4.897

4.  Complement factor H polymorphism in age-related macular degeneration.

Authors:  Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

5.  Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration.

Authors:  Sepideh Zareparsi; Kari E H Branham; Mingyao Li; Sapna Shah; Robert J Klein; Jurg Ott; Josephine Hoh; Gonçalo R Abecasis; Anand Swaroop
Journal:  Am J Hum Genet       Date:  2005-05-13       Impact factor: 11.025

6.  Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture.

Authors:  Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

7.  Complement factor H polymorphism and age-related macular degeneration.

Authors:  Albert O Edwards; Robert Ritter; Kenneth J Abel; Alisa Manning; Carolien Panhuysen; Lindsay A Farrer
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

8.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

9.  Global data on visual impairment in the year 2002.

Authors:  Serge Resnikoff; Donatella Pascolini; Daniel Etya'ale; Ivo Kocur; Ramachandra Pararajasegaram; Gopal P Pokharel; Silvio P Mariotti
Journal:  Bull World Health Organ       Date:  2004-12-14       Impact factor: 9.408

10.  Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration.

Authors:  Paul Hahn; Ying Qian; Tzvete Dentchev; Lin Chen; John Beard; Zena Leah Harris; Joshua L Dunaief
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

View more
  1 in total

1.  SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.

Authors:  Delu Song; Peiying Hua; Brian L VanderBeek; Joshua L Dunaief; Juan E Grunwald; Ebenezer Daniel; Maureen G Maguire; Daniel F Martin; Gui-Shuang Ying
Journal:  Retina       Date:  2021-07-01       Impact factor: 3.975

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.